CAMBRIDGE, England--(BUSINESS WIRE)--Apollo Therapeutics, a portfolio-based biopharmaceutical company rapidly advancing potentially transformative treatments based on breakthrough discoveries, has completed a $145 million (over £100 million) financing. The financing was led by Patient Square Capital, which will take a controlling position in the business, with participation from additional investors including Rock Springs Capital, Reimagined Ventures and UCL Technology Fund.
News
Leading pharmaceutical and biotech product development consultancy Boyds has added to its regulatory team with the appointments of Shalini Gupta and Sarah Stevenson in response to recent growth and the continued increase in demand for its dedicated regulatory services.
NOTTINGHAM, UK – 16 June, 2021 – Life Science Newswire – Leading Drug Discovery Contract Research Organisation Sygnature Discovery has announced the set-up of a state-of-the-art Early Candidate Developability Screening Group. Located at its headquarters in Nottingham, UK, the new service line will expand on the company’s offerings to customers by bridging into formal preclinical drug development and paving the way for clinical trials. |
Health, Safety and Biosafety Consultant, Dr Bishop Simon, will be presenting a free biosafety webinar in collaboration with the Institution of Occupational Safety and Health. This session offers insight into the controls used by safety professionals to protect our laboratory research scientist and the community around them, as they work to make the discoveries needed to advance the treatment of diseases.
Cambridge, UK, 14 June 2021: PhoreMost Ltd., the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’ disease targets, today announced it has appointed Dr Christian Dillon as Vice President of Biology. In this new role, Dr Dillon will work across all the Company’s areas of interest, including oncology, targeted protein degradation, and neurodegeneration, leading PhoreMost’s efforts to progress the novel targets identified by its SITESEEKER® platform towards drug discovery.
The next round of the Biomedical Catalyst will launch on 7th June. £18 Million is available to support industry-led research and development projects that seek to provide solutions to Health and Care challenges.
Air Products is pleased to announce that it has extended its agreement with One Nucleus for another two years. It means that One Nucleus members can benefit from preferential rates on liquid gases and associated equipment from Air Products until at least 2023.
Arecor Therapeutics plc
(“Arecor”, the “Company” or the “Group”)
ARECOR APPOINTS DR. LINDSEY FOULKES AS CHIEF OPERATING OFFICER
Cambridge, UK, 10 June 2021: Arecor Therapeutics plc (AIM: AREC), a globally focused biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces the appointment of Dr. Lindsey Foulkes as the Company’s Chief Operating Officer.
Arecor Therapeutics plc
(“Arecor”, the “Company” or the “Group”)
EXCLUSIVE FORMULATION STUDY COLLABORATION WITH PAR STERILE PRODUCTS TO DEVELOP A STABLE READY TO USE PRODUCT
Cambridge, UK, 7th June 2021: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that it has signed a formulation study agreement with Par Sterile Products, LLC, an Endo International plc company (“Par”).
Click here to view the June 2021 edition of eNews - an ON Helix preview.